A citation-based method for searching scientific literature

H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 472



David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl, Maximilian von Eynatten. Circulation 2014
Times Cited: 783




List of shared articles



Times cited

Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Hiddo J L Heerspink, Megumi Oshima, Hong Zhang, Jingwei Li, Rajiv Agarwal, George Capuano, David M Charytan, Jagriti Craig, Dick de Zeeuw, Gian Luca Di Tanna,[...]. Am J Kidney Dis 2022
5

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Hongyan Liu, Vikas S Sridhar, Jacinthe Boulet, Atit Dharia, Abid Khan, Patrick R Lawler, David Z I Cherney. Metabolism 2022
3


Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.
Omar Azzam, Vance B Matthews, Markus P Schlaich. Curr Opin Nephrol Hypertens 2022
1

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2022
0

Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
Wilfried Mullens, Pieter Martens, Jeffrey M Testani, W H Wilson Tang, Hadi Skouri, Frederik H Verbrugge, Marat Fudim, Massimo Iacoviello, Jennifer Franke, Andreas J Flammer,[...]. Eur J Heart Fail 2022
1

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo,[...]. Int J Mol Sci 2022
0


New Approaches to Diabetic Nephropathy from Bed to Bench.
Jun-Li Tsai, Cheng-Hsu Chen, Ming-Ju Wu, Shang-Feng Tsai. Biomedicines 2022
0

SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats.
Olha Kravtsova, Ruslan Bohovyk, Vladislav Levchenko, Oleg Palygin, Christine A Klemens, Timo Rieg, Alexander Staruschenko. Am J Physiol Renal Physiol 2022
0

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Hufang Zhou, Wenhua Peng, Fuyao Li, Yuelin Wang, Baofu Wang, Yukun Ding, Qian Lin, Ying Zhao, Guozhong Pan, Xian Wang. Front Cardiovasc Med 2022
0

SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
Alexia Piperidou, Charalampos Loutradis, Pantelis Sarafidis. J Hum Hypertens 2021
7

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
17

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
37

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
32

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021
3

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
32

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.
Rosalie A Scholtes, Michaël J B van Baar, Megan D Kok, Petter Bjornstad, David Z I Cherney, Jaap A Joles, Daniël H van Raalte. Nephrology (Carlton) 2021
3

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
39

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi,[...]. Sci Rep 2021
2


Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
5



Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
3

An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Taichi Minami, Akiko Kameda, Yasuo Terauchi. Expert Opin Pharmacother 2021
0

Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci,[...]. Front Med (Lausanne) 2021
4

Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease.
Suyan Duan, Fang Lu, Dandan Song, Chengning Zhang, Bo Zhang, Changying Xing, Yanggang Yuan. Front Endocrinol (Lausanne) 2021
3

Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
Mette V Østergaard, Thomas Secher, Michael Christensen, Casper Gravesen Salinas, Urmas Roostalu, Jacob Lercke Skytte, Ida Rune, Henrik H Hansen, Jacob Jelsing, Niels Vrang,[...]. Am J Physiol Renal Physiol 2021
5


Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure.
Masaki Nakagaito, Teruhiko Imamura, Shuji Joho, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa. BMC Cardiovasc Disord 2021
1

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
8